A heterologous vaccine regimen consisting of a first dose of the AstraZeneca vaccine and a second dose of the Pfizer vaccine induces a stronger immune response than a regimen consisting of two doses of the AstraZeneca vaccine.
It is slowly becoming clear that the immunity induced by SARS-CoV-2 vaccination is of overall better quality than that induced by COVID-19.
Infection with some parasitic worms may lead to an impaired immune response against pathogenic infections by other parasites, bacteria, and some viruses.
Early interactions of herpes simplex virus type 1 with the immune system involve both Langerhans cells and a newly characterized dendritic cell. Understanding the dynamics of these initial interactions of the virus with cells of the immune system may result in better strategies for HSV-1/-2 vaccines.
Accumulating data suggest that SARS-CoV-2 vaccination of pregnant and lactating people is safe and beneficial for both mother and child.
On February 27, 2021, the FDA issued an emergency use authorization for a one-dose SARS-CoV-2 vaccine developed by Janssen Pharmaceutica, a Belgium-based division of Johnson & Johnson.
